3-乙氧基-2-丁炔羧酸乙酯 | 998-91-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-乙氧基-2-丁炔羧酸乙酯
• 中文别名: 3-乙氧基-2-丁烯酸乙酯
• 英文名称: ethyl 3-ethoxy-2-butenoate
• 英文别名: Ethyl 3-ethoxybut-2-enoate
• CAS: 998-91-4
• 化学式: C₈H₁₄O₃
• mdl: MFCD00026932
• 分子量: 158.197
• InChiKey: ZOCYCSPSSNMXBU-UHFFFAOYSA-N

物化性质

• 熔点：
  30-32 °C(lit.)
• 沸点：
  195-200 °C(lit.)
• 密度：
  0.965
• 闪点：
  137 °F
• 稳定性/保质期：
  在常温常压下稳定，应避免与强氧化剂或酸接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险品运输编号：
  UN 1325 4.1/PG 2
• 储存条件：
  请将容器密封保存，并存放在阴凉、干燥处。

SDS

Name:	Ethyl 3-ethoxybut-2-enoate 97% Material Safety Data Sheet
Synonym:
CAS:	998-91-4

Section 1 - Chemical Product MSDS Name:Ethyl 3-ethoxybut-2-enoate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
998-91-4	Ethyl 3-ethoxybut-2-enoate	97%	213-652-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 998-91-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless - white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 86 - 88 deg C @14mmHg
Freezing/Melting Point: 30 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H14O3
Molecular Weight: 158

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 998-91-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 3-ethoxybut-2-enoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 998-91-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 998-91-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 998-91-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-乙氧基-2-丁炔羧酸乙酯 在 镍 作用下， 生成 3-乙氧基丁酸乙酯
  参考文献：
  名称：

  The Reduction of Ester Vinylogs¹

  摘要：

  DOI：

  10.1021/ja01231a005
• 作为产物：
  描述：

  ethoxy cyclobutenone 在 水 作用下， 生成 3-乙氧基-2-丁炔羧酸乙酯
  参考文献：
  名称：

  Cyclobutenone derivatives from ethoxyacetylene

  摘要：

  DOI：

  10.1021/jo00948a003

文献信息

• Regioselectivity of the alkylation of ambident anionic species on alumina or in the presence of ‘solid hexamethylphosphoric triamide’
  作者：Georges Bram、Niall Geraghty、Gérard Nee、Jacqueline Seyden-Penne

  DOI：10.1039/c39800000325

  日期：——

  C-Alkylation of the acetoacetate anions and of sodium naphthoxide is highly favoured on alumina, while O-alkylation of the acetoacetate anion predominates in tetrahydrofuran in the presence of solid hexamethylphosphoric triamide.

  在氧化铝上，乙酰乙酸根阴离子和萘氧基钠的C-烷基化是非常有利的，而乙酰乙酸根阴离子的O-烷基化在四氢呋喃中在固体六甲基磷酸三酰胺存在下占优势。
• [EN] IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017176961A1

  公开（公告）日：2017-10-12

  The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

  本发明提供了取代的咪唑[1,5-a]嘧啶基甲酰胺及其相关有机化合物，包含此类化合物的组合物，医疗试剂盒，以及使用此类化合物和组合物治疗医疗障碍的方法，例如，戈谢病，帕金森病，路易体病，痴呆症或多系统萎缩症。本说明书中描述的代表性的取代咪唑[1,5-a]嘧啶基甲酰胺化合物包括取代的2-杂环基-4-烷基-咪唑[1,5-a]嘧啶-8-甲酰胺化合物及其变体。
• [EN] PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2011163518A1

  公开（公告）日：2011-12-29

  The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

  本发明提供了公式I或公式II的化合物：(I)、(II)或其药用可接受的盐或酯，如本文所述。这些化合物及其组合物可用于治疗副粘病毒感染。这些化合物、组合物和方法特别适用于治疗人类呼吸道合胞病毒感染。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009062289A1

  公开（公告）日：2009-05-22

  Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

  公式I的化合物：其中c、R2、R3、R4、R5、R6、R7和R8按本说明定义，可用作HIV复制的抑制剂。
• Five Roads That Converge at the Cyclic Peroxy-Criegee Intermediates: BF₃-Catalyzed Synthesis of β-Hydroperoxy-β-peroxylactones
  作者：Vera A. Vil’、Gabriel dos Passos Gomes、Maria V. Ekimova、Konstantin A. Lyssenko、Mikhail A. Syroeshkin、Gennady I. Nikishin、Igor V. Alabugin、Alexander O. Terent’ev

  DOI：10.1021/acs.joc.8b02218

  日期：2018.11.2

  actones from silyl enol ethers, enol acetates, and cyclic acetals confirm that the β-peroxylactones indeed correspond to a deep energy minimum that connects a variety of the interconverting oxygen-rich species at this combined potential energy surface. The target β-hydroperoxy-β-peroxylactones were synthesized from β-ketoesters, and their silyl enol ethers, alkyl enol ethers, enol acetates, and cyclic

  我们发现通过BF 3催化的各种无环前体，β-酮酸酯及其甲硅烷基烯醇醚，烷基烯醇醚，烯醇乙酸酯和环状缩醛与H 2 O的BF 3催化环化反应，可合成获得β-氢过氧-β-过氧内酯。2个。引人注目的是，与起始原料的选择无关，这些反应收敛于相同的β-氢过氧-β-过氧内酯产物，即先前难以捉摸的Baeyer-Villiger反应的环状Criegee中间体的过氧类似物。由甲硅烷基烯醇醚，烯醇乙酸酯和环状缩醛形成β-氢过氧-β-过氧内酯的计算热力学参数证实，β-过氧内酯确实对应于连接各种相互转化的富氧物种的最低能量最小值。在这个组合的势能面。由β-酮酸酯合成了目标β-氢过氧-β-过氧内酯，并以30-96％的收率获得了它们的甲硅烷基烯醇醚，烷基烯醇醚，烯醇乙酸酯和环状缩醛。这些反应在温和的条件下进行，即使在可以预期替代氧化途径的情况下，也可以选择性地形成多种选择性选择性形成的β-氢过氧-β-过氧内酯。这些β-